Autoimmune Therapeutic Development Services
Advanced biomarker capabilities designed to meet the needs of autoimmune studies
For autoimmune indications, a fit-for-purpose plan can combine immune-cell dynamics, cytokine/chemokine profiles, receptor occupancy with PK/PD relationships, and tissue signatures to build a credible differentiation story.
.jpeg?width=343&height=396&name=AdobeStock_119321858%20(1).jpeg)
Operationalizing biomarker-driven autoimmune trials
Precision for Medicine supports autoimmune trial execution with reproducible MoA and PD readouts that connect immune dynamics to clinical outcomes, enabled by integrated end-to-end solutions.
Epiontis ID® assays are fully validated and can be rapidly set up to run
Epiontis ID® offers a dynamic biomarker strategy with over 35 validated immune cell assays, supporting clinical development across therapeutic areas. Our scientific team continuously expands the available cell types, often in response to client-specific needs. Beyond custom assay development, we integrate Epiontis ID® with complementary technologies to deliver a comprehensive biomarker solution. Study sponsors can select and combine any validated cell types into tailored panels for immune profiling and analysis.
Precision’s cell phenotyping technology, Epiontis ID, is ideal for use in autoimmune studies
Epiontis ID has been extensively used for immune monitoring in autoimmune studies across a range of indications, and has validated assays designed for specific autoimmune indications.
Below is data showing the number of studies Epiontis ID has been used for in various autoimmune indications.
| Indication | Number of studies | Number of samples | Study phase | Study years | Sample types |
|---|---|---|---|---|---|
Crohn's Disease |
4 |
9468 |
Phase 3 |
2018 |
Blood |
GvHD |
5 |
3411 |
Phase 3, research |
2016, 2017, 2018, 2019 |
Blood, tissue, PBMC, cells |
Psoriasis |
6 |
2834 |
Phase 1, 2, 4 |
2015, 2016, 2017, 2018 |
Blood, tissue |
Ulcerative Colitis |
2 |
1575 |
Phase 2 |
2015, 2016 |
Blood, tissue |
Asthma |
1 |
1350 |
Phase 2b |
2018 |
Blood |
Lupus |
2 |
1312 |
Phase 1, 2 |
2017, 2018 |
Blood |
Behcet's Syndrome |
1 |
672 |
Phase 4 |
2015 |
Blood |
Sjorgren's Syndrome |
5 |
479 |
Phase 1, 2a |
2015 |
Blood, DNA, PBMC |
Crohn's, Multiple Sclerosis/ Ulcerative Colitis |
2 |
390 |
Phase 1 |
2018 |
Blood |
Rheumatoid Arthritis |
2 |
375 |
Phase 1b, 2 |
2014 |
Blood |
Multiple Sclerosis |
2 |
330 |
Phase 1, 2 |
2016, 2017 |
Blood |
Celiac Disease |
1 |
204 |
Preclinical |
2016 |
Blood |
Atopic Dermatitis |
2 |
192 |
Phase 2a, 2b |
2018 |
Blood |
Myasthenia Gravis |
1 |
90 |
Phase 2 |
2018 |
DNA |
Peanut Allergy |
1 |
31 |
Preclinical |
2017 |
Blood |
IBD |
1 |
30 |
Preclinical |
2017 |
Tissue |
Diabetes |
2 |
20 |
Research, phase 2 |
2016, 2017 |
Blood, cells |
NASH |
1 |
48 |
Phase 1 |
2018 |
Blood |
